logo

For the Inventor, By the Inventor

Oxford, United Kingdom

Susan Mary Kingsman

This inventor holds 26 USPTO granted patents and 4 published patent applications and 7 EPO patents, primarily in Gene Therapy. Top assignees: Oxford Biomedica (UK) Limited, Oxford Biomedica, Inc., Oxford Gene Systems Limited. Active years: 1986-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Susan Mary Kingsman. Retrieved from https://idiyas.com/inventor/susan-mary-kingsman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 

% Patents Active = 65.4

 

Average Co-Inventor Count = 3.6

ph-index = 10

Forward Citations = 349(Granted Patents)


Location History:

  • Islip, GB (1986 - 2000)
  • Islip, Oxon OX5 2SF, GB (2003)
  • The Oxford Science Park, GB (2004)
  • Oxon, GB (2001 - 2009)
  • Oxford, GB (2006 - 2012)

Company Filing History:

goldMedal16 out of 53 
 
Oxford Biomedica (UK) Limited
 patents
silverMedal3 out of 5 
 
Oxford Biomedica, Inc.
 patents
bronzeMedal3 out of 3 
 
Oxford Gene Systems Limited
 patents
4. 2 out of 42 
 
Celltech Limited
 patents
5. 1 out of 85 
 
British Biotech Pharmaceuticals Limited
 patents
6. 1 out of 834,570 
Other
 patents

Years Active: 1986-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Peptide
Chemo-Immunotherapy
Vector
MHC Class I
Tumor Targeted
Retroviral Vectors
Lentiviral Vectors
Therapeutic Gene
Fusion Proteins
Anti-HIV Peptides
Gene Therapy
DNA Sequence
26 patents (USPTO):Explore Patents
1. 8147838 - Peptide (2012-04-03),
2. 8133681 - Chemo-immunotherapy method (2012-03-13),
3. 8084249 - Vector (2011-12-27),
4. 7888115 - MHC class I peptide epitopes from the human 5T4 tumor-associated antigen (2011-02-15),
5. 7635687 - Vector system (2009-12-22),
6. 7531648 - Vector encoding an antibody that binds 5T4 antigen (2009-05-12),
7. 7514546 - Antibodies (2009-04-07),
8. 7303910 - Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site (2007-12-04),
9. 7198784 - Retroviral vectors (2007-04-03),
10. 7074909 - Antibodies (2006-07-11),
11. 6852703 - Tumor targeted vector (2005-02-08),
12. 6808922 - Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site (2004-10-26),
13. 6800281 - Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases (2004-10-05),
14. 6669936 - Retroviral vectors (2003-12-30),
15. 6541219 - Therapeutic Gene (2003-04-01),

Title: The Innovative Legacy of Susan Mary Kingsman

Introduction:

Susan Mary Kingsman, a pioneering inventor hailing from Oxford, GB, has made significant strides in the field of immunotherapy with an impressive portfolio of 25 patents.

Latest Patents:

Among her recent patents is the groundbreaking development of peptide epitopes of the 5T4 antigen for use in immunotherapy. These epitopes play a crucial role in the diagnosis and therapy of cancer, showcasing Kingsman's dedication to advancing treatment options in oncology. Additionally, she has patented a chemo-immunotherapy method that involves administering an antigen alongside chemotherapeutic agents, opening new avenues for disease treatment and prevention.

Career Highlights:

Kingsman has left an indelible mark on renowned companies such as Oxford Biomedica (UK) Limited and Oxford Gene Systems Limited, where her innovative spirit and expertise have been instrumental in driving forward groundbreaking research and development in the medical field.

Collaborations:

Throughout her illustrious career, Susan Mary Kingsman has collaborated closely with esteemed professionals in the industry, including Alan John Kingsman and Christopher Robert Bebbington. These partnerships have fostered a culture of innovation and excellence, leading to the successful implementation of cutting-edge technologies and therapies.

Conclusion:

In conclusion, Susan Mary Kingsman's dedication to pushing the boundaries of medical innovation through her patents and collaborations underscores her invaluable contributions to the field of immunotherapy. Her work continues to inspire and pave the way for future advancements in the fight against cancer and other diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…